top of page

ANAVEX New Website - Untitled Page.png

Search

Assessment of ANAVEX 2-73 in a MECP2 Rett Syndrome Mouse Model

ANAVEX® Life Sciences Corp.
Feb 26, 2016
1 min read

2016 Epilepsy Pipeline Conference, San Francisco, California Christopher U. Missling, PhD

View Presentation

Recent Posts

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

bottom of page